Management of Memantine-Induced Dizziness
Discontinue memantine gradually if dizziness is intolerable, as this represents a recognized adverse effect that warrants deprescribing when it impairs quality of life and medication adherence. 1
Immediate Assessment
First, confirm that dizziness is specifically attributable to memantine rather than other causes:
- Rule out delirium, concurrent medical illness, or recent environmental changes that could explain symptoms 1
- Review all concurrent medications, particularly other agents that may contribute to dizziness
- Assess fall risk, as dizziness increases fall hazard and represents a safety concern affecting morbidity
Management Algorithm
Option 1: Dose Reduction (Preferred Initial Strategy)
Before complete discontinuation, consider dose reduction:
- Reduce current dose by 50% and maintain for 4 weeks 1
- Reassess tolerability at the lower dose
- If dizziness persists or remains intolerable, proceed to full discontinuation
- This approach may allow some patients to continue therapy at a tolerable dose
Option 2: Gradual Discontinuation (If Dose Reduction Fails)
Follow structured deprescribing protocol:
- Reduce dose by 50% every 4 weeks until reaching the initial starting dose (5 mg daily) 1
- After 4 weeks at starting dose, discontinue completely 1
- Monitor closely for 6-8 weeks post-discontinuation for cognitive, functional, or behavioral decline 1
Critical Considerations
Dizziness is explicitly listed as an intolerable side effect warranting memantine discontinuation in the 2020 Canadian Consensus Conference guidelines 1. The FDA label confirms dizziness occurs in 7% of memantine-treated patients versus 5% with placebo 2, and multiple studies identify it as a common adverse effect 3, 4, 5, 6.
Important Caveats:
Do NOT abruptly discontinue memantine - case reports document discontinuation syndrome with significant behavioral disturbance following abrupt cessation 7. Gradual tapering is essential.
Reinitiate if decline occurs: If the patient shows clinically meaningful worsening of cognition, function, or neuropsychiatric symptoms that appears related to memantine cessation, consider restarting at a lower dose 1
Alternative Treatment Considerations
After discontinuation, evaluate whether alternative dementia treatment is appropriate:
- Consider cholinesterase inhibitors (donepezil, rivastigmine, galantamine) if not already tried 8, 9
- Base selection on tolerability profile, adverse effects, ease of use, and cost 8
- Cholinesterase inhibitors have different side effect profiles (primarily gastrointestinal rather than dizziness) 4, 6
Context on Memantine Efficacy
The decision to discontinue should be made easier knowing that memantine shows only statistically significant but not clinically important cognitive improvements in most patients 8. The 2008 ACP/AAFP guidelines emphasize that benefits are "modest or even no benefit" for many patients, with no reliable way to predict responders 8. Therefore, discontinuing due to intolerable side effects that impair quality of life and increase fall risk is clinically justified.
Quality of life and safety take precedence over modest statistical benefits - particularly when dizziness increases fall risk, which can lead to fractures, hospitalization, and functional decline in elderly dementia patients.